FDA Approves Sanofi Inc.'s Dengue Vaccine

Date : 05/02/2019 @ 12:38AM
Source : Dow Jones News
Stock : Sanofi (SAN)
Quote : 83.07  0.39 (0.47%) @ 8:44AM
Sanofi share price Chart

FDA Approves Sanofi Inc.'s Dengue Vaccine

Sanofi (EU:SAN)
Historical Stock Chart

6 Months : From Apr 2019 to Oct 2019

Click Here for more Sanofi Charts.

By Maria Armental


Sanofi's dengue vaccine was approved in the U.S., the first vaccine cleared to treat the mosquito-borne virus in the country and U.S. territories like Puerto Rico, U.S. Virgin Islands, American Samoa and Guam.

The vaccine, Dengvaxia, was approved by the Food and Drug Administration to treat those aged 9 through 16, against the mosquito-borne virus.

The disease is complex to vaccinate against because it can be caused by four different strains of the same virus. Dengvaxia, first approved in Mexico in 2015, targets the four strains; but health regulators warn that it should only be given to those who have previously had a dengue infection, and live in areas where dengue is endemic.

Those who haven't had a previous dengue infection face a higher risk of contracting severe dengue when vaccinated with Dengvaxia.

It is unknown whether Dengvaxia is safe or protective for people living in areas where dengue isn't endemic or who travel to dengue endemic areas, the FDA said.


Write to Maria Armental at maria.armental@wsj.com


(END) Dow Jones Newswires

May 01, 2019 19:23 ET (23:23 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20191017 07:59:54